Press Releases

Press Releases

July 18, 2019
Iovance Biotherapeutics Appoints Friedrich Graf Finckenstein, M.D., as Chief Medical Officer
SAN CARLOS, Calif. , July 18, 2019 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced the appointment of Friedrich Graf Finckenstein ,
July 02, 2019
Iovance Biotherapeutics Provides Cervical Cancer Program Updates Following End of Phase 2 Meeting with U.S. Food and Drug Administration (FDA)
FDA agreed that the ongoing single-arm Phase 2 innovaTIL-04 study may be sufficient to support registration of LN-145 in advanced cervical cancer SAN CARLOS, Calif. , July 02, 2019 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel
June 11, 2019
Iovance Biotherapeutics Appoints Athena Countouriotis, M.D., to Board of Directors
SAN CARLOS, Calif., June 11, 2019 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced the appointment of Athena Countouriotis, M.D., to
May 31, 2019
Updated Results of Studies in Advanced Cervical Cancer and Melanoma Support Long-Term Efficacy of Iovance Tumor Infiltrating Lymphocyte (TIL) Therapy
Complete Response rate of 11 percent observed in the LN-145 study in cervical cancer Median duration of response has not been reached at 7.4 month median follow-up in the ongoing study of LN-145 in advanced cervical cancer Median duration of response has not been reached at 8.8 month median
May 31, 2019
Iovance Biotherapeutics to Participate in Upcoming Conferences in June
SAN CARLOS, Calif. , May 31, 2019 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced that the company plans to participate in the
May 29, 2019
Iovance Biotherapeutics Announces New Facility to Support U.S. Production of Tumor Infiltrating Lymphocyte Cell Therapy Products
Approximately 136,000 square foot facility to be built in the Philadelphia Navy Yard will allow for efficient commercial production SAN CARLOS, Calif. , May 29, 2019 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel cancer
May 22, 2019
Iovance Biotherapeutics Announces Breakthrough Therapy Designation for LN-145 for Treatment of Advanced Cervical Cancer Patients Who Have Progressed on or After Chemotherapy
SAN CARLOS, Calif. , May 22, 2019 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced that the U.S.
May 15, 2019
Iovance Biotherapeutics Announces Updates to Tumor Infiltrating Lymphocyte (TIL) Therapy Clinical Programs
Patients with advanced cervical cancer treated with LN-145 had an objective response rate of 44 percent Patients in Cohort 2 with advanced melanoma treated with lifileucel following failure of checkpoint inhibitors had objective response rate of 38 percent First patient dosed in IOV-COM-202; the
May 07, 2019
Iovance Biotherapeutics Reports First Quarter 2019 Financial Results and Provides Corporate Update
- First patient dosed in pivotal Cohort 4 in study of lifileucel in advanced melanoma; regulatory submission planned for late 2020 - - New interim data from melanoma Cohort 2 and cervical cancer studies to be presented in June at the 2019 American Society of Clinical Oncology ( ASCO ) meeting - -
May 02, 2019
Iovance Biotherapeutics to Participate in Upcoming Conferences in May
SAN CARLOS, Calif. , May 02, 2019 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced that the company plans to participate in the
May 01, 2019
Iovance Biotherapeutics to Host First Quarter 2019 Financial Results Conference Call and Webcast on Tuesday, May 7, 2019
SAN CARLOS, Calif. , May 01, 2019 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced that it will report its first quarter 2019
April 03, 2019
Iovance Biotherapeutics to Present New Data from Ongoing Studies of Tumor-Infiltrating Lymphocyte (TIL) Therapy at 2019 American Society of Clinical Oncology (ASCO) Meeting
Presentations to provide updated data from Cohort 2 of the innovaTIL-01 (C-144-01) study in advanced melanoma and the innovaTIL-04 (C-145-04) study in cervical cancer SAN CARLOS, Calif. , April 03, 2019 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc.
April 03, 2019
Iovance Biotherapeutics Announces Clinical Programs Update
- Design of cervical cancer study amended in anticipation for regulatory interactions -             -  Global IOV-COM-202 study to add new combination arm for patients with non-small cell lung cancer; IOV-LUN-201 study to close - SAN CARLOS, Calif. , April 03, 2019 (GLOBE NEWSWIRE) -- Iovance
April 02, 2019
Iovance Biotherapeutics Announces First Patient Dosed in Cohort 4 of Pivotal InnovaTIL-01 Study of Lifileucel in Metastatic Melanoma
- Patient dosing commenced in pivotal metastatic melanoma cohort - - Submission for regulatory approval of lifileucel is on target for late 2020 - SAN CARLOS, Calif. , April 02, 2019 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing
April 01, 2019
Iovance Biotherapeutics Presents Data at AACR Annual Meeting on T-Cell Diversity and Persistence in Patients Receiving Tumor Infiltrating Lymphocyte (TIL) Therapy Lifileucel
- Data from cohort 2 of the innovaTIL-01 study support polyclonal approach necessary to treat metastatic melanoma - SAN CARLOS, Calif. , April 01, 2019 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late stage biotechnology company developing novel cancer immunotherapies based
March 29, 2019
Iovance Biotherapeutics Announces April Scientific and Investor Presentations
SAN CARLOS, Calif. , March 29, 2019 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced that the company will present at the following
March 06, 2019
Iovance Biotherapeutics to Present at Upcoming Investor Conferences in March
SAN CARLOS, Calif. , March 06, 2019 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced that company management will participate and present at the
February 27, 2019
Iovance Biotherapeutics Reports Fourth Quarter and Full-Year 2018 Financial Results and Provides Corporate Update
- Patient Enrollment Commenced in the Registrational Cohort 4 in Study of Lifileucel in Advanced Melanoma - - FDA Granted Fast Track Designation for LN-145 for Treatment of Patients with Recurrent, Metastatic or Persistent Cervical Cancer - - Company to Host Conference Call at 4:30 pm EST Today -
February 26, 2019
Iovance Biotherapeutics was Granted Fast Track Designation for LN-145 for Cervical Cancer
SAN CARLOS, Calif., Feb. 26, 2019 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA ), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced that the U.S.
February 22, 2019
Iovance Biotherapeutics to Host Fourth Quarter and Year-End 2018 Financial Results Conference Call and Webcast on Wednesday, February 27, 2019
SAN CARLOS, Calif. , Feb. 22, 2019 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced that it will report its fourth quarter and year-end 2018
February 01, 2019
Iovance Biotherapeutics to Present at Upcoming Investor and Medical Conferences
SAN CARLOS, Calif. , Feb. 01, 2019 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced that the company will participate and present at the